Novel P2–P4 macrocyclic inhibitors of HCV NS3/4A protease by P3 succinamide fragment depeptidization strategy

Autor: Pompei, Marco, Francesco, Maria Emilia Di, Pesci, Silvia, Koch, Uwe, Vignetti, Sue Ellen, Veneziano, Maria, Pace, Paola, Summa, Vincenzo

Publikováno v: In Bioorganic & Medicinal Chemistry Letters 2010 20(1):168-174

Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.

Autor: Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yuca E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Scott SS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhao M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Paez Arango N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cruz Pico CX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Saridogan T; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shariati M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Class CA; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bristow CA; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vellano CP; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zheng X; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gonzalez-Angulo AM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Su X; Department of Bioinformatics and Computational Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tapia C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chen K; The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Akcakanat A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Francesco MED; Institute for Applied Cancer Science, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Draetta GF; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jones P; Institute for Applied Cancer Science, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heffernan TP; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Marszalek JR; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. fmeric@mdanderson.org.

Publikováno v: Cancer research [Cancer Res] 2021 Nov 01; Vol. 81 (21), pp. 5572-5581. Date of Electronic Publication: 2021 Sep 13.